Mefocit Tablet 50/850 Milligrams
Sitagliptin Phosphate Hydrate · Metformin Hydrochloride
Prescription medication · Combination
Kwangdong Pharmaceutical Co., Ltd.
MFDS item code 201506302 · Approved 2015.09.01
This product's status changed to Approval withdrawn on 2023.07.10. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medicine is used in conjunction with dietary and exercise therapy to help control blood sugar levels in patients with type 2 diabetes. It is used when previous treatment with diabetes medications has not been effective, or when monotherapy is inadequate for blood sugar control. If sufficient control is not achieved with either Metformin or Sitagliptin monotherapy, this medication can be substituted. Additionally, if blood sugar is not adequately controlled with Metformin and sulfonylureas, thiazolidinediones, or insulin, this medicine (Sitagliptin/Metformin combination) can be used to improve blood sugar control. It effectively helps in managing blood sugar levels with various combination therapies tailored to the patient's condition.
The dose of this drug for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with meals. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The starting dose of this drug should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the starting dose of this drug is 1 tablet of 50/500 mg twice daily. The dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended starting dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The starting dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the starting dose of metformin should take the patient's blood glucose level and current dose into account. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered with a sulfonylurea or insulin, reduction of the sulfonylurea or insulin dose may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to assess the safety and efficacy of switching to this drug in patients previously treated with other oral glucose-lowering drugs. Any change in treatment for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medicine is used in the treatment of diabetes and acts with two components to control blood sugar levels. When taking this medication, severe allergic reactions may occur, so if symptoms like rash, difficulty breathing, or swelling of the face or neck arise, you should stop taking the medication immediately and seek medical attention. Additionally, serious inflammation of the pancreas, known as pancreatitis, can occur; therefore, if sudden abdominal pain, nausea, vomiting, fever, or loss of appetite occurs while taking this medication, consult your doctor immediately. One component of this medication may be dangerous to patients with reduced kidney function, so it should not be used if kidney function is impaired. Patients with weakened heart function or those who have had an acute myocardial infarction, severe infections, or dehydration should also avoid this medication. Patients scheduled for imaging tests using contrast agents should discontinue this medication for a certain period before and after the test and can resume taking it only after confirming normal kidney function. It is safer for pregnant or nursing women not to take this medication. During treatment, be cautious of severe side effects like hypoglycemia or lactic acidosis, which can be triggered by irregular meals, intense exercise, or interactions with other medications. While taking this medication, regular blood tests and kidney function tests should be performed, and monitoring of vitamin B12 levels is also recommended. Excessive alcohol consumption can increase the risk of lactic acidosis, so it should be avoided. If surgery is to be performed, stop taking this medication 48 hours before the procedure and resume only after confirming recovery of kidney function post-surgery. During the course of this medication, be alert for symptoms of hypoglycemia, especially when used in conjunction with other blood sugar-lowering agents, as the risk of hypoglycemia may be increased. Severe joint pain or skin disorders may occur, so if these symptoms arise, consult your doctor. In case of overdose, seek immediate medical attention for appropriate treatment as some components can be removed through hemodialysis. Elderly patients may experience decreased kidney function, necessitating dosage adjustments and regular monitoring. This medication is known to have minimal impact on cardiovascular safety; however, if unusual symptoms occur while taking it, consult a healthcare professional.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air or moisture from entering, ideally at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the drug's effectiveness and prevent deterioration.
Pink oval film-coated tablet
Company packaging unit
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate Hydrate · Metformin Hydrochloride
Prescription medication · Combination
Kwangdong Pharmaceutical Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.